CAC
BIIB icon

Cowen and Company’s Biogen BIIB Stock Holding History

Cowen and Company’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,300
Closed -$5.25K – 577
2022
Q4 		$5.25K Buy
+4,300
New +$1.21M ﹤0.01% 478
2022
Q1 		– Sell
-7,500
Closed -$42K – 614
2021
Q4 		$42K Buy
+7,500
New +$1.93M ﹤0.01% 453
2021
Q3 		– Sell
-3,200
Closed -$39K – 605
2021
Q2 		$39K Buy
+3,200
New +$969K ﹤0.01% 427

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cowen and Company's BIIB Position: Q1 2024 in Review

Cowen and Company sold out of Biogen (BIIB) in Q1 2024, closing a stake of 3,326 shares — an estimated $861K sold.

Cowen and Company first reported a position in BIIB in Q2 2021 and held it in 6 quarters. The position peaked at $1.35M in Q2 2021. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

  • Cowen and Company reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 3,326 Biogen shares in Q1 2024, an estimated $861K.
  • Cowen and Company first reported a position in Biogen in Q2 2021 and held it in 6 quarters.
  • Cowen and Company's Biogen position peaked at $1.35M in Q2 2021.
  • 955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.